

## Durham Research Online

---

### Deposited in DRO:

03 November 2015

### Version of attached file:

Published Version

### Peer-review status of attached file:

Peer-reviewed

### Citation for published item:

Sim, N. and Gottschalk, S. and Pal, R. and Delbianco, M. and Degtyarik, D. and Razansky, D. and Westmeyer, G.G. and Ntziachristos, V. and Parker, D. and Mishra, A. (2015) 'Wavelength-dependent optoacoustic imaging probes for NMDA receptor visualisation.', *Chemical communications.*, 51 (82). pp. 15149-15152.

### Further information on publisher's website:

<http://dx.doi.org/10.1039/c5cc06277b>

### Publisher's copyright statement:

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.

### Additional information:

---

### Use policy

The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-profit purposes provided that:

- a full bibliographic reference is made to the original source
- a [link](#) is made to the metadata record in DRO
- the full-text is not changed in any way

The full-text must not be sold in any format or medium without the formal permission of the copyright holders.

Please consult the [full DRO policy](#) for further details.



Cite this: *Chem. Commun.*, 2015, 51, 15149

Received 27th July 2015,  
Accepted 24th August 2015

DOI: 10.1039/c5cc06277b

www.rsc.org/chemcomm

## Wavelength-dependent optoacoustic imaging probes for NMDA receptor visualisation†

Neil Sim,<sup>a</sup> Sven Gottschalk,<sup>b</sup> Robert Pal,<sup>a</sup> Martina Delbianco,<sup>a</sup> Oleksiy Degtyaruk,<sup>b</sup> Daniel Razansky,<sup>bc</sup> Gil G. Westmeyer,<sup>bde</sup> Vasilis Ntziachristos,<sup>bf</sup> David Parker<sup>\*a</sup> and Anurag Mishra<sup>\*b</sup>

**The cellular localisation and binding specificity of two NMDAR-targeted near-IR imaging probes has been examined by microscopy, followed by exemplification of MSOT to monitor simulated glutamate bursts in cellulo and a preliminary study in mice observing the signal in the brain.**

Glutamate (Glu) is an important excitatory chemical messenger in the central nervous system (CNS), involved in many signalling functions between neurons. Its release from synaptic vesicles to the synaptic cleft is stimulated by electrically induced calcium influx into the presynaptic terminal and its effects are induced following binding to postsynaptic receptors.<sup>1,2</sup> Ionotropic *N*-methyl-D-aspartate receptors (NMDARs) are widely localised on the post-synaptic cell membrane and play a crucial role in impaired neural circuit operations that incite many devastating phenomena of the brain.<sup>1,2</sup> Slight disturbances in the NMDAR signalling pathway may lead to neuropsychiatric pathologies such as schizophrenia, Alzheimer's disease, and certain mood disorders.<sup>3,4</sup>


Multi-spectral optoacoustic tomography (MSOT) is a non-invasive method that applies multi-wavelength illumination to identify the spectral signatures of any absorbers of interest.<sup>5,6</sup> MSOT has a penetration of several cm into living tissue,<sup>5</sup> high spatial resolution (100  $\mu$ m independent of photon scattering), ultrasensitive detection of intrinsic tissue chromophores and probes (nM), as well as real-time imaging capability.<sup>6</sup> However, MSOT will only develop beyond addressing haemodynamic changes,<sup>7</sup> if tailored optoacoustic (OA) imaging probes can be devised. Here, we introduce OA imaging probes that bind

selectively to NMDARs and non-invasively can track concentration changes of Glu in tissue with good sensitivity and spatio-temporal resolution.

This approach may not only be used to image receptor density but also may allow sensing of Glu concentration changes *via* MSOT. We have developed two NMDAR-targeted imaging probes, **L**<sup>1</sup> and **L**<sup>2</sup> (Scheme 1) for MSOT. These probes are based on a heptamethine cyanine dye, conjugated to both competitive and non-competitive antagonists for selective NMDAR-tagging. Receptor targeting *via* an antagonist-based approach is promising, as the receptors do not normally get internalised into cells *via* receptor mediated endocytosis.<sup>8</sup> Recently, the non-competitive antagonist, Ifenprodil,<sup>9</sup> has been conjugated to a red-fluorescent pentamethine cyanine dye<sup>10</sup> and an NMDAR antagonist has been linked to a Gd complex to create an MRI probe<sup>11</sup> for selective NMDAR imaging.

The core heptamethine cyanine dye precursor **5** (Scheme 1) is well suited as a strongly absorbing chromophore for use in MSOT. The synthesis began with construction of the heterocyclic indole ring, *via* quaternary ammonium salt formation and condensation (Scheme S1, ESI†). The amine precursors **10/12** were made using standard methodology, *via* alkylation, mesylation-amination, coupling, amide formation, and protection steps (Schemes S2 and S3, ESI†). **L**<sup>1</sup> and **L**<sup>2</sup> were obtained by coupling the amine **10/12** and the mono-acid, **5**, [HATU/DIPEA] in anhydrous DMF (Scheme S4, ESI†).

The presence of the negatively charged sulfonate groups reduces non-specific binding to endogenous proteins.<sup>12</sup> The



**Scheme 1** OA imaging probes for NMDAR-tagging.

<sup>a</sup> Department of Chemistry, Durham University, South Road, Durham DH1 3LE, UK. E-mail: david.parker@durham.ac.uk

<sup>b</sup> Institute for Biological and Medical Imaging, Helmholtz Zentrum München, Neuherberg 85764, Germany. E-mail: anurag.mishra@helmholtz-muenchen.de

<sup>c</sup> School of Medicine, Technische Universität München (TUM), Munich 80333, Germany

<sup>d</sup> Institute of Developmental Genetics, Helmholtz Zentrum, Neuherberg 85764, Germany

<sup>e</sup> Department of Nuclear Medicine, Technische Universität München, Munich 80333, Germany

<sup>f</sup> Chair for Biological Imaging, Technische Universität München, Munich 80333, Germany

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c5cc06277b



absorption spectra of each probe showed broad absorption bands centred at 776 nm, with a secondary band at 712 nm (Scheme S4, ESI†). The optoacoustic signal of **L**<sup>1</sup> and **L**<sup>2</sup> replicate the absorption spectra in aqueous solution (Scheme S4, ESI†).

The extinction coefficient of each dye at 776 nm was 240 000 M<sup>-1</sup> cm<sup>-1</sup>, consistent with an intense  $\pi \rightarrow \pi^*$  ( $0 \rightarrow 0$  vibronic) transition. The shoulder at 712 nm is also  $\pi \rightarrow \pi^*$  mode, relating to the  $0 \rightarrow 1$  or  $0 \rightarrow 2$  vibronic transitions.<sup>13</sup> These absorption properties makes them excellent candidates as NMDAR-targeted probes for MSOT, with the maximum wavelength of absorption falling in the near-infrared (NIR) window where the majority of endogenous chromophores do not strongly absorb. In this region, light scattering is relatively low resulting in greater light penetration, allowing images to be obtained from deeper within the body. The emission spectra of **L**<sup>1</sup> and **L**<sup>2</sup> were measured ( $\lambda_{\text{exc}}$  776 nm) and were structurally the same, with one main emission band at 801 nm, giving a Stokes' shift of 25 nm (Scheme 1). The quantum yields (5–10%) fell in the range of similar dye structures.<sup>14</sup>

The in cellulo studies were performed on differentiated NSC-34 cells expressing receptor subunits NMDAR-2B and NMDAR-1 at high densities, as shown earlier.<sup>11,15</sup> None of these probes exhibited significant cytotoxicity after 24 h (MTT), at concentrations of up to 100  $\mu\text{M}$ . To determine the live cell-surface co-localisation profile of **L**<sup>1</sup> and **L**<sup>2</sup>, two optical microscopic techniques were explored to visualise NMDARs on live neuronal cells (NSC-34). The probes were first visualised upon cell surface NMDARs-tagging using epifluorescence microscopy following direct excitation ( $\lambda_{\text{exc}} > 750$  nm). Differentiated NSC-34 cells expressing NMDARs were incubated with the probes [**5** (as a control), **L**<sup>1</sup> or **L**<sup>2</sup> (10  $\mu\text{M}$ , 30 min)] and then washed with Hank's balanced salt solution (HBSS) to remove unbound probe. **L**<sup>1</sup> and **L**<sup>2</sup> showed complete NMDAR-probe visualisation in fluorescence mode (Fig. S3, ESI†). Larger signal intensity was detected from cells treated with **L**<sup>1</sup>, suggesting a higher receptor affinity. No signal was obtained from cells upon incubation with the control dye **5**, consistent with specific binding of **L**<sup>1</sup> and **L**<sup>2</sup> on the NMDARs (Fig. S3, ESI†).

A second microscopic technique was used to confirm that the probes were at the cell surface. Using a FRET-based assay, **L**<sup>1</sup> and **L**<sup>2</sup> were acceptors, excited by a non-internalised Eu(III) complex<sup>16</sup> [**Eu**·**L**]<sup>3-</sup> (Fig. 1), as the donor. Excitation of [**Eu**·**L**]<sup>3-</sup> at 365 nm led to population of the dye excited state. Spectral overlap of the  $\Delta J = 4$  emission band of the donor with the absorption spectrum of the acceptor led to excitation of **L**<sup>1</sup> and **L**<sup>2</sup>, indicating donor and acceptor in close proximity (Fig. 1). Emission from the acceptor was also observed above 780 nm.

A study of the energy transfer process was first performed *in vitro* to confirm this possibility. As a reference NIR dye, the commercially available **Dy-647-NH**<sub>2</sub> was chosen as the acceptor. Changes in the [**Eu**·**L**]<sup>3-</sup> emission lifetime were monitored as a function of the concentration of NIR dyes [**L**<sup>1</sup> and **Dy-647-NH**<sub>2</sub>]. Stern-Volmer analysis showed 65% energy transfer efficiency between [**Eu**·**L**]<sup>3-</sup> and **L**<sup>1</sup>, less than that calculated for **Dy-647-NH**<sub>2</sub> (93%), due to reduced spectral overlap (Fig. 1). The differentiated NSC-34 cells were incubated with a 10  $\mu\text{M}$  solution of either **L**<sup>1</sup> or




Fig. 1 **L**<sup>1</sup> dye absorption (green) and [**Eu**·**L**]<sup>3-</sup> emission (red) spectra, ( $\text{H}_2\text{O}$ , pH 7.2, 295 K). Table: quenching studies for [**Eu**·**L**]<sup>3-</sup> with **L**<sup>1</sup> or **Dy-647-NH**<sub>2</sub> as acceptor. (data ( $\pm 5\%$ ), 295 K, 50 mM HEPES, 50 mM NaCl, pH 7.4;  $\lambda_{\text{ex}}$  332 nm). Weak Eu transitions at 750 and 800 nm ( $\Delta J = 5$  and  $\Delta J = 6$  manifolds) are not shown.


**L**<sup>2</sup> for 30 minutes and washed to remove unbound probe. The cells were treated with fresh buffer containing 20  $\mu\text{M}$  of [**Eu**·**L**]<sup>3-</sup>, and imaged using a modified Zeiss Axiovert 200M inverted microscope.<sup>17</sup> Excitation at 365 nm and observation of the time-gated emission (6  $\mu\text{s}$  delay) above 780 nm demonstrated that both **L**<sup>1</sup> and **L**<sup>2</sup> gave rise to a localisation profile at the cell surface (Fig. 2B and D), with **L**<sup>1</sup> appearing to label the cells more readily than **L**<sup>2</sup>. Using the same cell preparation, live cell imaging studies were also performed consistent with the hypothesis of selective probe-receptor tagging at the cell surface (Fig. 2D). Confirmation of cell-surface localisation was achieved by repeating the loading experiment with a co-incubation of the commercially available, plasma membrane stain, CellMask Orange (5  $\mu\text{g mL}^{-1}$  for 5 min) (Fig. 2A and C).

The cellular NMDAR-probe binding specificity was further proven by studies on NMDAR-negative cells (NIH 3T3 mouse skin fibroblast cells). These cells were incubated with a solution of either **L**<sup>1</sup> or **L**<sup>2</sup> (10  $\mu\text{M}$ , 30 min.), washed to remove unbound probe and treated with [**Eu**·**L**]<sup>3-</sup> (20  $\mu\text{M}$ ). No localisation profile was observed, strengthening the case for receptor-mediated localisation of **L**<sup>1</sup> and **L**<sup>2</sup> with differentiated NSC-34 cells.

One further characteristic for these probes is the ability to bind reversibly at the NMDAR, with an affinity competitive with endogenous Glu. Since **L**<sup>1</sup> was visualised on the cell surface receptors, the binding of this probe after a simulated 'Glu burst' was assessed. The differentiated NSC-34 cells were consecutively incubated with **L**<sup>1</sup> (10  $\mu\text{M}$ , 30 min,  $3 \times$  HBSS wash), Cell Mask Orange (5  $\mu\text{g mL}^{-1}$ , 5 min,  $2 \times$  HBSS wash) and then treated with fresh buffer containing 20  $\mu\text{M}$  of [**Eu**·**L**]<sup>3-</sup>. The cells were imaged and the average intensity was recorded in triplicate. These cells were washed with a Glu-rich ( $2 \times$ , 1 mM) medium and then treated with buffer containing 20  $\mu\text{M}$  of [**Eu**·**L**]<sup>3-</sup>. This sequence resulted in a ten-fold drop in fluorescence intensity (Fig. 2F and G), compared to the original cell staining experiment (Fig. 2B), whilst the non-specific membrane dye maintained the same intensity (Fig. 2E).

To demonstrate the suitability of the probes for OA detection, the probes were assessed by MSOT after interaction with cell surface NMDARs on differentiated NSC-34 cells. These experiments were






**Fig. 2** Live cell fluorescence microscopy images of differentiated NSC-34 cells following treatment with **L**<sup>1</sup> and **L**<sup>2</sup> (10  $\mu$ M, 30 min, 37  $^{\circ}$ C and 5% CO<sub>2</sub>) followed by Cell Mask Orange (CMO) (5  $\mu$ g mL<sup>-1</sup>–5 min) showing cell surface localisation. (A–D) (A) visualisation of plasma membrane by CMO ( $\lambda_{\text{ex}}/\lambda_{\text{em}}$  = 525/590 nm); (B) **L**<sup>1</sup> visualisation by FRET using [Eu-**L**]<sup>3+</sup> ( $\lambda_{\text{ex}}/\lambda_{\text{em}}$  = 365/780 nm). (C and D) Analogous to images (A and B) but incubation with **L**<sup>2</sup>. (E and F): incubation with **L**<sup>1</sup>, followed by CMO, followed by glutamate wash (2 $\times$ , 1 mM); (E) plasma membrane visualisation by CMO; (F) no detectable signal of **L**<sup>1</sup> ( $\lambda_{\text{ex}}/\lambda_{\text{em}}$  = 365/780 nm), showing the reversibility of binding in the presence of Glu. (G) Gaussian distribution plot of recorded intensity count of a unified stained cell standardising the average contrast transfer function (CTF) intensities to the maximum brightness of the original loading experiment. Original simultaneous loading experiment of **L**<sup>1</sup> (10  $\mu$ M), (green 13 600 counts) compared to the post-glutamate wash (purple 160 counts, 1.2%). [Bars = 20  $\mu$ m,  $\times$ 63/1.40 NA oil, 1300  $\times$  1030 pixels/frame,  $d_{\text{xy}}$  = 138 nm], [bars = 20  $\mu$ m].

conducted using a small animal MSOT scanner. In brief, about 10<sup>6</sup> differentiated NSC-34 cells were treated with 20  $\mu$ M of either **5**, **L**<sup>1</sup> or **L**<sup>2</sup> for 30 minutes, washed thoroughly to remove any unbound probe and were then re-suspended in a 1 : 1 mixture of fresh buffer and a 3% agar solution. The agar solution generated a scattering pattern mimicking tissue scattering. Images were obtained by scanning wavelengths between 700–900 nm in 5 nm steps, with 20 averages each (Fig. 3 and Fig. S4, ESI<sup>†</sup>).

**L**<sup>1</sup> clearly labels NSC-34 cells, generating a strong optoacoustic signal (Fig. 3C).<sup>18</sup> As a control, untreated cells (Fig. 3A) and cells treated with the non-targeted heptamethine cyanine dye, **5** (Fig. 3B) did not show any OA signal, suggesting that the receptor-binding moiety of **L**<sup>1</sup> binds to the cell surface NMDARs and is responsible for the observed OA signal. However, cell labelling with **L**<sup>2</sup> (20  $\mu$ M, 30 min) gave rise to only a faint OA signal (Fig. 3D) replicating results obtained from fluorescence microscopy when comparing the labelling efficiencies of **L**<sup>1</sup> vs. **L**<sup>2</sup>. Fig. 3 (right panel) shows the wavelength dependence of the optoacoustic signals of cells treated with **L**<sup>1</sup>/**L**<sup>2</sup>. The cell bound OA spectrum of **L**<sup>1</sup> was significantly different from the OA spectrum of supernatant **L**<sup>1</sup> (Fig. 3.1). An enhanced intensity around 700 nm and a decreased intensity around 780 nm suggests that bound and unbound probe can be distinguished and will potentially be observable in an *in vivo* model, in the presence of endogenous photo-absorbers. This switchable intensity was confirmed upon treating cells with **L**<sup>1</sup>, washed twice with HBSS and recording the



**Fig. 3** Live cell OA signal of differentiated NSC-34 cells following treatment with **5**, **L**<sup>1</sup> or **L**<sup>2</sup> (each 20  $\mu$ M, 30 min, 37  $^{\circ}$ C and 5% CO<sub>2</sub>). (Left) (A) Untreated cells; (B) cells treated with control dye, **5**, no OA signal; (C) cells treated with **L**<sup>1</sup> (D) cells treated with **L**<sup>2</sup> (E) cells treated with the corresponding antagonist, Ifenprodil (40  $\mu$ M, 10 min), followed by treatment with **L**<sup>1</sup> (C and F) cells treated with **L**<sup>1</sup> and washed with Glu (2 $\times$ , 1 mM), strong reduction in OA signal. (Right) Absorbance spectrum of **5**, **L**<sup>1</sup> and **L**<sup>2</sup> that are fed into the unmixing algorithm. Wavelength-dependent analysis of NSC-34 labelled with **5**, **L**<sup>1</sup> or **L**<sup>2</sup>. (1–2). Compared optoacoustic signal of **L**<sup>1</sup>/**L**<sup>2</sup> (supernatant) vs. cell bound-**L**<sup>1</sup>/**L**<sup>2</sup>.

normalised absorption spectrum (Fig. S5, ESI<sup>†</sup>). The absorption maximum for cell-bound **L**<sup>1</sup> clearly undergoes a hypsochromic shift to around 694 nm, compared to the absorbance maxima at 774 nm for **L**<sup>1</sup> alone. The cell bound OA spectrum of **L**<sup>2</sup> was the same as the OA spectrum of supernatant **L**<sup>2</sup> (Fig. 3.2).

The absorption spectra involve  $\pi \rightarrow \pi^*$  transitions that are affected by the local solvent polarity. A hypsochromic shift in the cell-bound-**L**<sup>1</sup> absorption maxima suggests that the probe is in a less polar environment, as compared to the probe alone. The similar behaviour of Indocyanine Green (ICG) has been explained by Landsman; ICG shows a hypsochromic shift when the plasma concentration increased.<sup>19</sup> It is also known that the ifenprodil-binding site is buried deep within the interface between the GluN1 and GluN2B subunit ATD dimers, suggesting an induced-fit mechanism of binding, with dissociation likely to involve opening of the GluN2B ATD bi-lobed structure.<sup>20</sup> As the binding site is deep within the NMDAR cleft, the cavity is more hydrophobic than in normal solution, leading to the shift in absorption wavelength. Furthermore, a competition experiment was performed to assess the cellular labelling of **L**<sup>1</sup> in the presence of the antagonist Ifenprodil. Differentiated NSC-34 cells were treated with a 40  $\mu$ M solution of Ifenprodil for 10 minutes (2 $\times$  HBSS wash), then incubated with a 20  $\mu$ M solution of **L**<sup>1</sup> for 30 minutes (2 $\times$  HBSS wash) and imaged using MSOT. Pre-treating cells with the NMDAR-binding moiety of **L**<sup>1</sup> before loading the cells with **L**<sup>1</sup> gave a diminished OA signal (Fig. 3E). Such behaviour suggests that the NMDAR binding efficiency of **L**<sup>1</sup> is slightly less



than with Ifendopril. Similar behaviour was reported for a cyanine dye conjugate.<sup>10</sup> The ability of **L**<sup>1</sup> to be displaced from the NMDAR by the natural ligand L-Glu was demonstrated using MSOT. Differentiated NSC-34 cells were treated with 20  $\mu$ M solution of **L**<sup>1</sup> for 30 minutes and washed with L-Glu-rich (1 mM, 2 $\times$  wash) HBSS before being imaged. A greatly diminished OA signal was observed (Fig. 3F), showing that **L**<sup>1</sup> is displaced by a simulated L-Glu burst, in accord with the fluorescence microscopy experiments.

To visualise the imaging probes under the skull *via* MSOT, preliminary *in vivo* studies were undertaken. The motor cortex of the mouse has a high expression of NMDARs.<sup>1,20</sup> Therefore, **L**<sup>1</sup> and **5** were injected intracranially into the motor cortex. MSOT successfully visualised **L**<sup>1</sup> deep inside the brain tissue, while **5** was not visualised, presumably being flushed away by the blood flow. An *ex vivo* cryoslicer-imaging study (30 min post-injection) showed that fluorescent probe **L**<sup>1</sup> was inside the brain (Fig. S6A and B, ESI<sup>†</sup>).

In summary, the results obtained concerning the localisation, cellular specificity and reversibility of binding suggest that **L**<sup>1</sup> and **L**<sup>2</sup> are binding to the cell surface *via* their NMDAR-binding moieties. The reversibility of **L**<sup>1</sup> binding to the NMDAR was shown *via* MSOT studies, showing that Glu addition leads to probe release from the receptor site. The work paves the way for development of probes capable of visualising NMDAR densities in models of neuropsychiatric disease, suggesting that dynamic changes in Glu concentration *in vivo* may be measured *via* non-invasive MSOT imaging, serving as an alternative to lower resolution PET imaging.

We thank the European Research Council [ERC-ADvG: 266804 (NS, RP, DP) and 233161 (VN), ERC-StG: 260991 (SG,

DR) and 311552 (GGW)], the Helmholtz Alliance ICAMED (AM, GGW).

## Notes and references

- 1 *Neurotransmitters and Neuromodulators: Handbook of Receptors and Biological Effects*, Wiley-VCH, 2006.
- 2 S. Brady, G. Siegel, R. W. Albers and D. Price, *Basic Neurochemistry*, Academic Press, 7th edn, 2005.
- 3 S. E. Lakhan, M. Caro and N. Hadzimechalis, *Front. Mol. Psychiatry*, 2013, **4**, 1.
- 4 T. Abel and R. S. Zukin, *Curr. Opin. Pharmacol.*, 2008, **8**(1), 57.
- 5 M. L. James and S. S. Gambhir, *Physiol. Rev.*, 2012, **92**, 897.
- 6 A. Taruttis and V. Ntziachristos, *Nat. Photonics*, 2015, **9**, 219.
- 7 S. Gottschalk, T. F. Fehm, X. L. Deán-Ben and D. Razansky, *J. Cereb. Blood Flow Metab.*, 2015, **35**, 531.
- 8 N. Sim and D. Parker, *Chem. Soc. Rev.*, 2015, **44**, 2122.
- 9 I. J. Reynolds and R. J. Miller, *Mol. Pharmacol.*, 1989, **36**, 758.
- 10 P. Marchand, J. Beceril-Ortega, L. Mony, C. Bouteiller, P. Paoletti, O. Nicole, L. Barré, A. Buisson and C. Perrio, *Bioconjugate Chem.*, 2011, **23**, 21.
- 11 N. Sim, R. Pal, D. Parker, J. Engelmann, A. Mishra and S. Gottschalk, *Org. Biomol. Chem.*, 2014, **12**(46), 9389.
- 12 F. M. Hamann, J. B. R. Fau-Pauli, M. P. J. Fau-Grabolle, W. G. M. Fau-Frank, W. A. F. W. Fau-Kaiser, D. K. W. Fau-Fischer, U. F. D. Fau-Resch-Genger, I. R.-G. U. Fau-Hilger and I. Hilger, *Mol. Imaging*, 2011, **10**, 258.
- 13 D. S. Pisoni, L. Todeschini, A. C. A. Borges, C. L. Petzhold, F. S. Rodembusch and L. F. J. Campo, *J. Org. Chem.*, 2014, **79**, 5511.
- 14 M. Y. Berezin, K. Guo, W. Akers, J. Livingston, M. Solomon, H. Lee, K. Liang, A. Agee and S. Achilefu, *J. Biochem.*, 2011, **50**, 2691.
- 15 N. Sim, S. Gottschalk, R. Pal, J. Engelmann, D. Parker and A. Mishra, *Chem. Sci.*, 2013, **4**(8), 3148.
- 16 M. Delbianco, L. Lamarque and D. Parker, *Org. Biomol. Chem.*, 2014, **12**, 8061.
- 17 R. Pal and A. Beeby, *Methods Appl. Fluoresc.*, 2014, **2**, 037001.
- 18 A. Rosenthal, *IEEE Trans. Med. Imaging*, 2010, **29**, 1275.
- 19 M. L. J. Landsman, G. Kwant, G. A. Mook and W. G. Zijlstra, *J. Appl. Physiol.*, 1976, **40**, 575.
- 20 E. Karakas, N. Simorowski and H. Furukawa, *Nature*, 2011, **475**, 24.

